NIO Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? NIO Inc. trades at $4.55 (market cap $11.59B), while Regeneron Pharmaceuticals Inc trades at $797 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.1× NIO Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | REGN | |
|---|---|---|
Market Cap | $11.59B | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $812.27 |
52-Week Low | $4.44 | $555.51 |
Enterprise Value | $10.82B | $76.77B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
NIO's stock trades at $4.555, down 5.5% in the last session amid a bearish technical signal and negative cash flow trends. The company shows revenue growth with 2025 sales reaching $87.49 billion, but remains unprofitable with a net loss of $15.57 billion. Recent news highlights delivery growth and policy support for EVs in China, yet investor sentiment is mixed due to competitive pressures and high cash burn.
The outlook is cautious; while analyst consensus leans bullish with 54% buy ratings, fundamental weaknesses in profitability and negative equity pose significant risks. Upside depends on sustained revenue expansion and cost control, but volatility from market sentiment and execution challenges warrants careful monitoring for investors.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Trailing returns across standard periods
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →